| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | B02 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.5 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |